Alpha 2.0
Login Register
» Authors » Enrico Ricevuto

Enrico Ricevuto

Explore the profile of Enrico Ricevuto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 90
Citations 943
Followers 0
Related Specialties
Oncology
General Medicine
Critical Care
Top 10 Co-Authors
Corrado Ficorella
Gemma Bruera
Paolo Marchetti
Katia Cannita
Giovanni Luca Gravina
Claudio Festuccia
Alberto Gulino
Stefano Guadagni
Luigi Frati
Giampiero Porzio
Published In
Int J Oncol
Oncotarget
Breast Cancer Res Treat
Support Care Cancer
Prostate
Affiliations
Soon will be listed here.
Recent Articles
11.
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
Bruera G, Ricevuto E
Front Oncol . 2020 Mar; 10:172. PMID: 32154172
Cancer treatments induce symptoms/signs superimposing on individual patient's clinical status, determining heterogenous toxicity syndromes (TS). We reviewed intensive first line triplet chemotherapy-based regimens in metastatic gastro-intestinal cancers (mGI), based on...
12.
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study
Guadagni S, Clementi M, Mackay A, Ricevuto E, Fiorentini G, Sarti D, et al.
J Cancer Res Clin Oncol . 2020 Feb; 146(5):1273-1290. PMID: 32088781
Background: Hepatic artery infusion (HAI) and drug selection by liquid biopsy precision oncotherapy are under investigation for the multidisciplinary treatment of unresectable colorectal liver metastases (CRCLM) in progression after systemic...
13.
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, et al.
Lung Cancer . 2019 Dec; 140:59-64. PMID: 31881412
Objectives: The incidence of any and of severe-grade immune-related adverse events (irAEs) with second-line nivolumab monotherapy is 31-65 % and 2-5 % respectively. While potentially serious and even fatal, in...
14.
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay A, et al.
J Cancer Res Clin Oncol . 2019 Oct; 146(1):205-219. PMID: 31620896
Background: Third line innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have both been proposed for the treatment of unresectable not responsive recurrent rectal cancer (URRC). In...
15.
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an...
Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, et al.
BMC Cancer . 2019 Oct; 19(1):960. PMID: 31619203
Background: Neuroendocrine tumors (NETs) are heterogeneous, widely distributed tumors arising from neuroendocrine cells. Gastrointestinal (GI)-NETs are the most common and NETs of the rectum represent 15, 2% of gastrointestinal malignancies....
16.
Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
Capoluongo E, La Verde N, Barberis M, Bella M, Buttitta F, Carrera P, et al.
Diagnostics (Basel) . 2019 Oct; 9(4). PMID: 31600986
In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for . The number of labs offering this test is continuously increasing. The...
17.
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
Facchini G, Rossetti S, Berretta M, Cavaliere C, Scagliarini S, Vitale M, et al.
J Transl Med . 2019 Aug; 17(1):296. PMID: 31464635
Background: This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods:...
18.
Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
Guadagni S, Fiorentini G, Mambrini A, Masedu F, Valenti M, Mackay A, et al.
Oncotarget . 2019 Jun; 10(39):1-13. PMID: 31231460
Background: Innovative systemic treatments and loco-regional chemotherapy by hypoxic pelvic perfusion (HPP) have been proposed for unresectable recurrent rectal cancer (URRC). Regorafenib and trifluridine-tipiracil reported significantly increased PFS 1.9-2.0 months,...
19.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Bruera G, Massacese S, Pepe F, Malapelle U, Dal Mas A, Ciacco E, et al.
Ther Adv Med Oncol . 2019 Jun; 11:1758835919846421. PMID: 31205502
Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line wild-type and the prediction of individual...
20.
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives
Gori S, Barberis M, Bella M, Buttitta F, Capoluongo E, Carrera P, et al.
Crit Rev Oncol Hematol . 2019 Jun; 140:67-72. PMID: 31176273
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic...